NIH R01 · 2025
Targeting EP300 epigenomic control in neuroblastoma
Resistance to conventional therapy is a common source of cancer morbidity and mortality. Many tumors show intratumoral heterogeneity in cell state, where cells shift between epigenetically-controlled cell states under the selective pressures of treatment. These states may have differential resistance to therapy, and are marked by distinct epigenetically-controlled transcriptomes. The processes by which tumors convert between epigenetically-specified states has been challenging to study, since tumors are commonly marked by a high mutational load, which can obscure the contribution of cell state. Intriguingly, the pediatric high-risk tumor neuroblastoma (NB) is a heterogenous and lethal tumor…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.